Zoetis announced on October 20, 2026, that the U.S. Food and Drug Administration approved Convenia RTU for Dogs, a single-injection treatment for susceptible bacterial skin infections. The company expects the product to become available to veterinarians in the first quarter of 2027.
Key Takeaways
- One injection administered by a veterinary professional can provide up to 14 days of antibiotic treatment.
- The more concentrated formulation delivers the same dose in a smaller volume than existing Convenia.
- The new formulation is approved only for dogs and must not be used in cats.
Table of Contents
- Convenia RTU aims to simplify antibiotic dosing
- Approval covers specific infections in dogs
- Commercial availability is expected in early 2027
- Conclusion
Convenia RTU aims to simplify antibiotic dosing
Zoetis’ Convenia RTU approval announcement describes a treatment designed to remove the need for owners to administer daily oral antibiotics at home. A veterinary professional gives the injection, avoiding missed or irregular doses during the treatment period.
The practical change is in administration rather than a new treatment category. Zoetis said the more concentrated formulation makes single-injection treatment easier for dogs of all sizes, particularly medium and large breeds, because the required dose can be delivered in a smaller volume.
Abhay Nayak, executive vice president and president of U.S. commercial operations at Zoetis, described the product as an extension of the established Convenia portfolio. The original Convenia received FDA approval in 2008 for susceptible bacterial skin infections in both dogs and cats.
| Item | Details |
|---|---|
| Covered skin infections | Secondary superficial pyoderma, abscesses and wounds. |
| Target bacteria | Susceptible strains of Staphylococcus pseudintermedius and Streptococcus canis (Group G). |
| Listed side effects | Vomiting, diarrhea, decreased appetite or anorexia, and lethargy. |
Approval covers specific infections in dogs
Convenia RTU for Dogs contains cefovecin and is administered by subcutaneous injection in a veterinary clinic. Its approval covers specified skin infections caused by susceptible bacteria, rather than every skin condition or infection.
Unlike the original Convenia, the RTU formulation must not be used in cats because of a toxicity risk. It also should not be used in animals with a history of allergic reactions to penicillins or cephalosporins. People with known hypersensitivity to those antibiotic classes should avoid exposure.
Commercial availability is expected in early 2027
The approval expands Zoetis’ dermatology portfolio, but regulatory clearance and commercial availability are separate milestones. The company’s first-quarter 2027 availability target remains an expectation, not a completed launch.
Zoetis positioned the product as a way to broaden access to single-injection treatment, especially for larger dogs. The announcement did not provide a product revenue forecast or quantify the approval’s expected contribution to company earnings.
Conclusion
The next milestone is Zoetis’ planned first-quarter 2027 availability to veterinarians, when the newly approved formulation is expected to move into commercial use.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
